Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00751530 · ClinicalTrials.gov registry record

BRAVO: Background Regimen of Raltegravir on Virologic Outcome

A clinical trial of HIV Infections, sponsored by Community Research Initiative of New England.

Completed
Registry status
442
Enrollment target
15
Study locations

NCT00751530: Completed study of HIV Infections, sponsored by Community Research Initiative of New England.

NCT00751530 is a study of HIV Infections that has completed, run by Community Research Initiative of New England. The registered enrollment target is 442 participants, roughly in line with the 445-participant average among 542 other HIV Infections trials with a reported enrollment target. The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00751530, a study of HIV Infections, has completed, sponsored by Community Research Initiative of New England.

COMPLETED
Registry status
442 participants
Enrollment target
15
Study locations

Study Summary

This is a retrospective chart review of participants in raltegravir expanded access program and will compare virologic response in regimens not containing a protease inhibitor in the antiretroviral background regimen to regimens containing a protease inhibitor in the background regimen.

Conditions Studied

HIV Infections

Interventions

  • DRUG raltegravir

Study Locations (15)

California

  • Light Source Medical - Los Angeles
  • AIDS Healthcare Foundation - Los Angeles
  • Synergy Hematology and Oncology - Los Angeles
  • Quest Clinical Research - San Francisco

District of Columbia

  • Dupont Circle Physicians Group - Washington D.C.
  • Capital Medical Associates PC - Washington D.C.

Massachusetts

  • Community Research Initiative - Boston
  • Community Research Initiative - West - Springfield

New York

  • Infectious Diseases and HIV Medicine Immunodeficiency Clinic - Buffalo
  • Bellman, MD - New York

Connecticut

  • Connecticut Health Care Group - Glastonbury

Florida

  • Orlando Immunology Center - Orlando

Illinois

  • Ruth M. Rothstein CORE Center - Chicago

Pennsylvania

  • Mounzer, MD - Philadelphia

Trial Details

FieldValue
Enrollment Target 442 participants
Start Date 2008-03-01
Est. Completion 2009-06-15

Sponsor

Community Research Initiative of New England

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00751530

The ClinicalTrials.gov registry entry for NCT00751530 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 442 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 445-participant average among 542 other HIV Infections trials with a reported enrollment target. The listed sponsor is Community Research Initiative of New England, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which raltegravir is the first listed.

NCT00751530 reports 15 study locations spanning 9 distinct geographic areas - top geographies include California, District of Columbia, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00751530 about?

NCT00751530 is a clinical study titled "BRAVO: Background Regimen of Raltegravir on Virologic Outcome". This is a retrospective chart review of participants in raltegravir expanded access program and will compare virologic response in regimens not containing a protease inhibitor in the antiretroviral background regimen to regimens containing a protease inhibitor in the background regimen.

What is the current status of trial NCT00751530?

This trial is currently completed. The enrollment target is 442 participants. The study started on 2008-03-01. Estimated completion is 2009-06-15.

What conditions does trial NCT00751530 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00751530?

The interventions under investigation include: raltegravir (DRUG).

Who is sponsoring clinical trial NCT00751530?

This trial is sponsored by Community Research Initiative of New England, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00751530 being conducted?

This trial has 15 study locations across California, Connecticut, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.